Advanced Search
Tao Hua, Kong Cheng, Lu Jincheng. Phase Ⅱ Study of Intensity-Modulated Radiotherapy Combined with 5-Fluorouracil and Nedaplatin Chemotherapy in Recurrent Esophageal Carcinoma after Curative Operation[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1261-1264. DOI: 10.3971/j.issn.1000-8578.2012.10.026
Citation: Tao Hua, Kong Cheng, Lu Jincheng. Phase Ⅱ Study of Intensity-Modulated Radiotherapy Combined with 5-Fluorouracil and Nedaplatin Chemotherapy in Recurrent Esophageal Carcinoma after Curative Operation[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1261-1264. DOI: 10.3971/j.issn.1000-8578.2012.10.026
shu

Phase Ⅱ Study of Intensity-Modulated Radiotherapy Combined with 5-Fluorouracil and Nedaplatin Chemotherapy in Recurrent Esophageal Carcinoma after Curative Operation

  • Department of Radiotherapy，Jiangsu Cancer Hospital，Nanjing 210009，China

More Information
  • Received Date: November 15, 2011
  • Revised Date: March 27, 2012
    Graphical Abstract
    • Abstract
  • Objective To analyze the feasibility and safety of postoperative recurrent esophageal carcinoma patients treated by intensity-modulated radiotherapy combined with 5-Fluorouracil(5-Fu) and nedaplatin chemotherapy. Methods Forty-four esophageal carcinoma patients suffered recurrence after their definitive resection in our department from June 2009 to June 2010.Intensity-modulated radiotherapy combined with 5-Fu and nedaplatin chemotherapy was performed in the patients(gross tumor volume,GTV) of IMRT was prescribed to 60 Gy/30f，2.0 Gy/f and 5-Fu and nedaplatin concurrent chemotherapy was used by 5-Fu 750 mg/（m2·d），d1~5，nedaplatin 80 mg/（m2·d），d1 at week 1 and week 4.The primary endpoint was 1-year survival rate and the second endpoint was toxicity related to the treatment. Results The overall response rate (CR+PR) was 86%（38/44）.1- and 2-year overall survival rate was 72.7% and 60%,respectively.1- and 2-year progression-free survival rate was 63.6% and 36.6%,respectively.Univariate analysis outcome showed that only recurrent site was related with prognosis （χ2=22.848，P=0.000）.All the patients undergone this treatment smoothly.Grade Ⅰ,Ⅱ and Ⅲ leukocytopenia was observed in 16% (7/44)，50% (22/44)，and 34% (15/44) patients，respectively.Grade I,and II digestive tract toxicity was observed in 45% (20/44)，55% (24/44) patients，respectively.Grade Ⅰ,and Ⅱ liver/renal toxicity was observed in 77% (34/44)，and 23% (10/44) patients，respectively.Over grade 3 digestive tract and liver/renal toxicity were not found.All the toxicities were gone after corresponding therapy. Conclusion Concurrent chemotherapy with 5-Fu and nedaplatin plus intensity-modulated radiotherapy is an effective and feasible regimen and would be considered as a better option for postoperative recurrent esophageal carcinoma patients,which could be deserved to be applied to phase Ⅲ clinical trial.
    • FullText(HTML)
    • References (16)
  • [1]
    Jemal A,Bray F,Center MM,et al.Global Cancer Statistics [J].CA Cancer J Clin,2011,61(2):69-90.
    [2]
    Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-49.
    [3]
    Enzinger PC,Mayer RJ.Esophageal cancer [J].N Engl J Med,2003,349(23):2241-52.
    [4]
    Abate E,DeMeester SR,Zehetner J,et al.Recurrence after esophagectomy for adenocarcinoma:defining optimalfollow-up intervals and testing[J].J Am Coll Surg,2010,210(4):428-35.
    [5]
    Kunisaki C,Makino H,Takagawa R,et al.Surgical outcomes in esophageal cancer patients with tumor recurrenceafter curative esophagectomy [J].J Gastrointest Surg,2008,12(5):802-10.
    [6]
    Wang YX,Zhu SC,Li R,et al.Radiotherapy for postoperative regional recurrence in esophageal carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2005,14(2):86-9.[王玉祥,祝淑钗,李任,等.食管癌术后区域性复发的放疗[J].中华放射肿瘤学杂志,2005,14(2):86-9.]
    [7]
    Zhang JR,Yang J,Lv Y,et al.Effect of radiotherapy on loco-regional recurrence of esophageal carcinoma aftersurgery[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2010,19(4) :302-5.[张瑾熔,杨蛟,吕茵,等.91例术后局部复发转移食管癌放疗疗效和预后分析[J].中华放射肿瘤学杂志,2010,19(4) :302-5.]
    [8]
    Jin J,Wang LH,Yin WB,et al.Radiotherap for postoperative anastomosis recurrence in esophageal carcinoma[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2000,9(2):87-9.[金晶,王绿化,殷蔚伯,等.食管癌根治术后吻合口复发的放疗[J].中华放射肿瘤学杂志,2000,9(2):87-9.]
    [9]
    Lu JC,Kong C,Tao H.Radiotherapy with or without concurrent chemotherapy for lymph node recurrence afterradical surgery of thoracic esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2010,78(3):710-4.
    [10]
    Carlisle JG,Quint LE,Francis IR,et al.Recurrent esophageal carcinoma:CT evaluation after esophagectomy [J].Radiology,1993,189(1):271-5.
    [11]
    Nemoto K,Ariga H,Kakuto Y,et al.Radiation therapy for loco-regionally recurrent esophageal cancer aftersurgery [J].Radiother Oncol,2001,61(2):165-8.
    [12]
    Raoul JL,Le Prisé E,Meunier B,et al.Combined radiochemotherapy for postoperative recurrence of oesophagealcancer[J].Gut,1995,37(2):174-6.
    [13]
    Nishimura Y,Koike R,Nakamatsu K,et al.Concurrent chemoradiotherapy with protracted infusion of 5-Fu andCisplatin for postoperative recurrent or residual esophageal cancer[J].Jpn J Clin Oncol,2003,33(7):341-5.
    [14]
    Uchida N,Takeda Y,Hojo K,et al.Sequence-dependent antitumour efficacy of combination chemotherapy ofnedaplatin,a novel platinum complex,with 5-fluorouracil in an in vivo murine tumour model[J].Eur JCancer,1998,34(11):1796-801.
    [15]
    Nemoto K,Matsushita H,Ogawa Y,et al.Radiation therapy combined with cis-diammine-glycolatoplatinum(Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer[J].Am J Clin Oncol,2003,26(1):46-9.
    [16]
    Jingu K,Nemoto K,Matsushita H,et al.Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer[J].BMCCancer,2006,6:50.
    • Related Articles

  • Related Articles

    [1]CAO Wenjing, WANG Yulin, ZHAI Yuqing, ZHANG Zongliang, YUAN Jiangshui, SONG Weiqing. Expression and Clinical Significance of MIS18BP1 in Bladder Cancer Tissues[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 163-168. DOI: 10.3971/j.issn.1000-8578.2024.23.1041
    [2]ZHANG Yuanyuan, FANG Zhaoqin, LIANG Chao. Screening of Genes Involved in Hepatoma Cells SMMC-7721 Stress Response Induced by Different Stressors[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 463-467. DOI: 10.3971/j.issn.1000-8578.2016.06.006
    [3]Pei Feng, Zhu Yi. Clinical Significance of Cytokeratin18 Fragments in Diagnosis of Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(04): 439-441. DOI: 10.3971/j.issn.1000-8578.2012.04.018
    [4]YANG Guang-min, LI Shou-qing, MA Yin-fu, WEI Bing-bing, SHI Yang, TAN Yan. Anti-tumor Immunotherapy Effect of Co-expression Genetic Vaccine MAGE-1/IL-18[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 294-297. DOI: 10.3971/j.issn.1000-8578.2010.03.014
    [5]YANG Sheng, LU Hui-shan, CHEN Xiang-qi, LIN Ting-yan, LI Zhi-ying, KANG Ming-qiang. Effect of IL-18 on Growth and Apoptosis of Lewis Lung Cancer Xenografts in C57BL/6 Mice[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 563-565. DOI: 10.3971/j.issn.1000-8578.2009.07.007
    [6]ZHAO Hong-xia, WANG Yan-kui, LUO Bing, YIN Guang-jie. Influence of HPV18E6 Small Interfering RNA on p21,VEGF,Bax and Bcl-2 Genes in HeLa Cells[J]. Cancer Research on Prevention and Treatment, 2009, 36(04): 261-264. DOI: 10.3971/j.issn.1000-8578.2009.04.001
    [7]YANG Qin, CHEN Hong-lei, LIU Ming-qiu, FANG Zhong. PCR-SSCP Analysis of FADD Gene Mutation in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 162-164. DOI: 10.3971/j.issn.1000-8578.442
    [8]GAO Yan-e, YANG Hui-ping, ZHANG Ju, GUO Jin-zhu, LIU Ning-xia, YAN Xiao-jun. Cloning and Sequencing of Human Papillomavirus Type 18 L1 Gene from Cervical Cancer Tissue[J]. Cancer Research on Prevention and Treatment, 2006, 33(03): 159-161. DOI: 10.3971/j.issn.1000-8578.441
    [9]LI Ji-mei, LI Chun-hai, WANG Qin-qin, et al, . Detect ion of MUC1 and GST-P Gene by means of RT-PCR in Axillary Lymph Nodes Taken from Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 351-353. DOI: 10.3971/j.issn.1000-8578.1357
    [10]Luo YuanHui, . The Point Mutation of Ras and p53 Genes in Paraffin-embedded Gastric Cancer Tissues by PCR-RFLP Analysis[J]. Cancer Research on Prevention and Treatment, 1995, 22(2): 68-71.

Catalog

    Get Citation
    PDF
    XML
    Article views (2305) PDF downloads (659) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：11642325 Visits today：9674

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return